U.S. Healthtech Stock News

NasdaqGS:QS
NasdaqGS:QSAuto Components

Is QuantumScape’s Eagle Line Launch And Licensing Pivot Altering The Investment Case For QS?

QuantumScape recently appointed defense-industry veteran Ross Niebergall to its board and, earlier in February, brought its Eagle Line pilot production for solid-state lithium-metal cells online, enabling shipments to customers for testing and integration. Together with its capital-light licensing blueprint and expanded production rights through Volkswagen’s PowerCo subsidiary, these moves reshape how QuantumScape pursues commercialization and industrial scale-up. Against this backdrop,...
NasdaqGS:BNTX
NasdaqGS:BNTXBiotechs

Assessing BioNTech (NasdaqGS:BNTX) Valuation After Founders’ Planned Exit And Weakening COVID-19 Revenues

BioNTech (NasdaqGS:BNTX) is back in focus after its co founders, CEO Ugur Sahin and Chief Medical Officer Ozlem Tureci, said they will leave by the end of 2026 to start a new early stage mRNA company. See our latest analysis for BioNTech. The leadership news comes after a weak run for the stock, with a 7 day share price return of 10.16% and a 30 day share price return of 16.63%. The 1 year total shareholder return of 8.32% and 3 year total shareholder return of 29.66% point to fading momentum...
NasdaqGS:INTA
NasdaqGS:INTASoftware

Intapp (INTA) Valuation Check After Omnes Capital DealCloud Win Draws Fresh Investor Attention

Intapp (INTA) is back on investor radars after Omnes Capital, a European private equity firm focused on the energy transition, selected Intapp’s DealCloud platform for marketing and investor relations workflows. See our latest analysis for Intapp. The Omnes Capital win comes after a volatile stretch for Intapp’s stock. A 1 day share price return of 4.06% has taken the latest share price to $25.65. However, a 90 day share price return of 40.32% and 1 year total shareholder return of 56.73%...
NYSE:ARES
NYSE:ARESCapital Markets

Assessing Ares Management (ARES) After A 26% Monthly Slide In The Share Price

If you are wondering whether Ares Management is attractively priced right now, you are not alone, especially with sentiment around alternative asset managers constantly shifting. The stock last closed at US$101.76, after a 7.5% decline over the past week and a 25.9% decline over the past month, while the 3 year and 5 year returns of 46.1% and 116.1% tell a different story over longer periods. Recent coverage has focused on Ares Management as a key player in private credit and alternative...
NYSE:DHI
NYSE:DHIConsumer Durables

Is It Time To Reevaluate D.R. Horton (DHI) After The Recent Share Price Pullback

If you have been wondering whether D.R. Horton is reasonably priced or offering value at current levels, this article will walk through what the numbers are really saying about the stock. The share price closed at US$140.49, with returns of 12.1% over 1 year, 48.5% over 3 years and 76.6% over 5 years. Over the last 7 days and 30 days the share price has declined by 4.6% and 14.3% respectively, and the year-to-date return is a 3.6% decline. Recent news around D.R. Horton has focused on its...
NYSE:WRB
NYSE:WRBInsurance

Weighing W. R. Berkley (WRB) After Recent Share Price Weakness

If you are wondering whether W. R. Berkley is fairly priced or offering value right now, the starting point is to look closely at what the current share price actually reflects. The stock most recently closed at US$68.76, with returns of a 1.7% decline over 7 days, a 3.9% decline over 30 days, a 0.9% decline year to date, 11.7% over 1 year, 81.7% over 3 years and 135.1% over 5 years. This gives you a mix of short term weakness and longer term strength to weigh up. Recent news around W. R...
NasdaqGS:CTAS
NasdaqGS:CTASCommercial Services

Assessing Cintas (CTAS) Valuation After Recent Mixed Share Price Performance

Why Cintas Is On Investors’ Radar Today Cintas (CTAS) has been drawing attention after a mixed stretch in recent trading, with a small gain over the past day but weaker performance over the past week and month. Given that context, some investors are revisiting the company’s fundamentals, including its reported US$10.8b in revenue and US$1.9b in net income, to assess how the current share price of US$194.28 aligns with those results. See our latest analysis for Cintas. That small 1-day share...
NYSE:GSL
NYSE:GSLShipping

Assessing Global Ship Lease (GSL) Valuation After Strong Earnings, Dividend Moves And Contracted Revenue Backlog

Global Ship Lease (GSL) is back on investors’ radar after reporting fourth quarter and full year 2025 earnings and declaring a quarterly cash dividend on its 8.75% Series B preferred shares. See our latest analysis for Global Ship Lease. The earnings beat and preferred dividend news come after a mixed few weeks for the share price, with a 9.61% 3 month share price return and a much stronger 1 year total shareholder return of 72.07%. This suggests momentum has been building over time despite...
NasdaqGS:TMC
NasdaqGS:TMCMetals and Mining

Assessing TMC The Metals Company (TMC) Valuation After NOAA Clears Key Deep Sea Mining Application

TMC the metals (TMC) is back in focus after the National Oceanic and Atmospheric Administration said the company’s consolidated application for a deep sea exploration and commercial recovery permit is in substantial regulatory compliance. See our latest analysis for TMC the metals. That regulatory milestone has arrived after a volatile period, with the latest share price at $5.97 and a 1 year total shareholder return of about 220% alongside a very large 3 year total shareholder return. This...
NYSE:VZ
NYSE:VZTelecom

Verizon News On Vestberg Move Frontier Deal And Fiber Focus

Hans Vestberg, former CEO of Verizon Communications (NYSE:VZ), has been appointed Senior Operating Advisor at Consello. Current Verizon leadership discussed the planned acquisition of Frontier Communications and a sharper customer-driven focus at a recent Morgan Stanley conference. Management highlighted plans to expand fiber reach and bundled broadband and wireless offerings as part of Verizon's next phase. For you as an investor, these updates sit on top of Verizon's core position in U.S...
NYSE:SPOT
NYSE:SPOTEntertainment

Spotify (SPOT) Valuation Check After Upgraded Earnings Outlook And Renewed Growth Optimism

Spotify Technology (SPOT) is back in focus after earnings estimates were revised sharply higher, with projections pointing to very large current quarter growth and more than 30% full year earnings expansion. See our latest analysis for Spotify Technology. The latest earnings revisions come after a choppy stretch for the stock, with a 7 day share price return of an 8.69% decline and a 90 day share price return of a 13.67% decline. This comes even though the 3 year total shareholder return of...
NasdaqGS:DXCM
NasdaqGS:DXCMMedical Equipment

Assessing DexCom (DXCM) Valuation As Conference Highlights Growth In Glucose Monitoring Technology

Conference spotlight and why DexCom (DXCM) is on investor radars DexCom (DXCM) is in focus as it presents new clinical findings and product updates at the Advanced Technologies and Treatments for Diabetes Conference in Barcelona, while recent results have highlighted revenue and earnings growth. See our latest analysis for DexCom. At a share price of US$64.24, DexCom has seen a 5.7% decline over the past month and a 3.5% year to date share price return. In comparison, the 1 year total...
NasdaqGS:MRCY
NasdaqGS:MRCYAerospace & Defense

Mercury Systems Acquisition Brings Critical Manufacturing In House For Defense Programs

Mercury Systems (NasdaqGS:MRCY) has acquired SolderMask, Inc., adding specialized manufacturing capabilities and intellectual property. The deal brings in skilled personnel and assets that directly support more than 20 active Mercury programs tied to critical defense work. The acquisition is intended to accelerate production efficiency and strengthen delivery commitments across key customer contracts. Mercury Systems, trading at $78.16, has seen a 68.0% return over the past year and a 69.1%...
NasdaqGM:KYMR
NasdaqGM:KYMRBiotechs

Can Kymera Therapeutics’ (KYMR) Oral Degraders Redefine Its Long-Term Edge Over Biologic Rivals?

Kymera Therapeutics recently advanced its first IRF5-directed oral therapy, KT-579, into human clinical testing and reported Phase 1b data for its oral STAT6 degrader KT-621, which appeared comparable or better than injectable dupilumab in a large inflammatory disease market. This progress positions Kymera as a pioneer in oral protein degraders that aim to match biologic-like efficacy while potentially offering more convenient, small-molecule treatment options. We’ll now examine how Kymera’s...
NasdaqCM:PLUG
NasdaqCM:PLUGElectrical

How Plug’s STAMP Exit And New CEO Appointment At Plug Power (PLUG) Has Changed Its Investment Story

In early March 2026, Plug Power finalized a major pivot by canceling its planned green hydrogen facility at New York’s STAMP site, while installing longtime sales executive Jose Luis Crespo as CEO, President, and a Class III director amid ongoing class action lawsuits tied to past project and DOE loan disclosures. At the same time, Plug Power reported higher 2025 revenue of US$709.92 million and a smaller net loss of US$1.63 billion than the prior year, suggesting early effects from Project...
NYSE:BX
NYSE:BXCapital Markets

A Look At Blackstone (BX) Valuation After Recent Share Price Volatility

Blackstone stock after recent performance Blackstone (BX) has drawn fresh attention after a period where the share price showed a 4.6% gain over the past day but declines over the past week, month and past 3 months. See our latest analysis for Blackstone. That 4.6% 1 day share price gain to $106.78 comes after a weaker spell, with 30 day and year to date share price returns of 20% and 32.8% declines. However, the 3 year total shareholder return of 38.1% and 5 year total shareholder return of...
NYSE:CF
NYSE:CFChemicals

CF Industries Faces DOJ Scrutiny And Questions Over Fertilizer Pricing Power

Senator Josh Hawley has accused CF Industries Holdings (NYSE:CF) of price gouging in its fertilizer business. He has urged the US Department of Justice to pursue an antitrust investigation into the company’s pricing practices. The DOJ is now examining whether CF Industries' fertilizer pricing has harmed farmers and competition. This scrutiny adds legal and political risk in addition to prior attention on fertilizer supply, costs, and global trade disruptions. CF Industries is a major...
NasdaqGS:DOCU
NasdaqGS:DOCUSoftware

A Look At DocuSign (DOCU) Valuation As AI Upgrades And Pricing Changes Draw Focus Before Earnings

Board refresh and AI focus draw attention ahead of DocuSign earnings DocuSign (DOCU) heads into its upcoming fourth quarter fiscal 2026 earnings report with several fresh storylines, including a new independent director appointment and expanding AI driven agreement tools. The company recently added Brian Roberts to its board as an independent Class I director, while also rolling out Iris powered features, testing new eSignature Professional pricing, and partnering with Anthropic on AI...
NasdaqGS:TTEK
NasdaqGS:TTEKCommercial Services

Is Tetra Tech (TTEK) Attractive After Recent Share Price Pullback And Mixed Valuation Signals

If you are wondering whether Tetra Tech shares are offering fair value right now, this article walks through what the current price could mean for long term investors. The stock last closed at US$32.18, with a 7.7% decline over the past week, a 20.4% decline over the past month, and returns of 11.3% over 1 year, 17.9% over 3 years, and 28.8% over 5 years. Recent coverage has focused on Tetra Tech as a US listed commercial services company and on how its current share price compares with...
NasdaqGS:MDGL
NasdaqGS:MDGLBiotechs

Is Rezdiffra’s Near‑US$1 Billion Debut Reshaping The Investment Case For Madrigal Pharmaceuticals (MDGL)?

Madrigal Pharmaceuticals recently reported that its MASH drug Rezdiffra generated nearly US$1.00 billion in its first full year on the market, reinforcing the company’s leading position in this disease area. This rapid commercial traction, coupled with management’s expectation for continued robust net sales growth in 2026, has attracted heightened attention from both institutional investors and short-sellers. Next, we’ll examine how Rezdiffra’s nearly US$1.00 billion first-year sales...
NYSE:PIPR
NYSE:PIPRCapital Markets

Assessing Piper Sandler (PIPR) After Recent Share Price Weakness And Capital Markets Activity

If you are wondering whether Piper Sandler Companies' current share price really reflects its underlying worth, or if the recent run leaves room for value, this article walks through that question step by step. The stock last closed at US$282.30, with returns showing a 3.8% decline over 7 days, a 17.4% decline over 30 days, a 19.3% decline year to date, a 14.2% gain over 1 year and a very large 3 year and 5 year return. Recent coverage around Piper Sandler Companies has focused on its role...
NYSE:HUBS
NYSE:HUBSSoftware

HubSpot (HUBS) Valuation Check After Recent Share Price Rebound And Analyst Discount

HubSpot (HUBS) is back on investor radars after a recent share price move, with the stock closing at $264.30 and showing mixed returns across the past week, month, and past 3 months. See our latest analysis for HubSpot. That 2.59% 1 day share price gain to US$264.30 comes after a 26.26% 30 day share price return. However, the year to date share price return and 1 year total shareholder return are both sharply negative, hinting that recent momentum is more of a rebound than a sustained...
NYSE:U
NYSE:USoftware

Unity Insider Selling Raises Questions As Margins Improve And Growth Slows

Unity Software (NYSE:U) has seen significant insider selling activity while reporting expanding operating margins. At the same time, the company is working through revenue growth challenges that have drawn fresh attention from investors. The mix of insider sales, margin improvement, and pressure on growth is raising new questions about Unity's internal outlook and business direction. For investors watching Unity Software at a share price of $19.43, the recent pattern of insider selling...
NYSE:AXP
NYSE:AXPConsumer Finance

American Express Buyback And Guidance Shift Refocuses Travel Driven Growth

American Express (NYSE:AXP) has launched a $16b share repurchase program, signaling a major round of capital returns to shareholders. The company has also raised its full year 2026 guidance, citing robust travel demand and expansion in its premium cardmember base. International travel volumes have moved above pre pandemic levels and contributed to a 15% rise in total network volume. For you as an investor, this news comes at a time when NYSE:AXP shares trade around $299.96, after a 15.3%...